Liver stiffness measurement as a predictive tool of clinically significant portal hypertension in patients with compensated hepatitis C virus or alcohol-related cirrhosis

被引:157
|
作者
Lemoine, M. [1 ]
Katsahian, S. [2 ]
Ziol, M. [3 ]
Nahon, P. [1 ]
Ganne-Carrie, N. [1 ]
Kazemi, F. [1 ]
Grando-Lemaire, V. [1 ]
Trinchet, J. -C. [1 ]
Beaugrand, M. [1 ]
机构
[1] Hop Jean Verdier, AP HP, Serv Hepatol, F-93143 Bondy, France
[2] Hop St Louis, AP HP, Dept Biostat & Informat Med, Paris, France
[3] Hop Jean Verdier, Dept Anatomopathol, F-93143 Bondy, France
关键词
D O I
10.1111/j.1365-2036.2008.03825.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Hepatic venous pressure gradient (HVPG) is the gold standard for assessing the presence and the severity of portal hypertension (PHT). Liver stiffness measurement (LSM) is a non-invasive method for liver fibrosis assessment. Aims To assess the relationship between LSM and HVPG in patients with compensated cirrhosis related to hepatitis C virus (HCV) or alcohol and to define the performance and the best cut-off of LSM for the diagnosis of PHT in these patients. Methods Between January 2004 and September 2006, we studied all the consecutive patients with compensated HCV or alcohol-related-cirrhosis referred for transjugular liver biopsy with HVPG measurement and LSM performed the same day. Results Ninety-two patients were eligible, 44 had HCV related-cirrhosis and 48 alcoholic cirrhosis. LSM was positively correlated to HVPG in both groups. The area under the receiver operating characteristic curve for the diagnosis of significant PHT was 0.76 +/- 0.07 in HCV patients (best cut-off at 20.5 kPa) and 0.94 +/- 0.03 (best cut-off at 34.9 kPa) in alcoholic patients. Conclusions Liver stiffness measurement and HVPG were significantly correlated in patients with compensated cirrhosis because of HCV infection or alcohol. LSM could predict significant PHT in both these groups of patients with a higher cut-off and a better performance in alcoholic patients.
引用
收藏
页码:1102 / 1110
页数:9
相关论文
共 50 条
  • [21] Deleterious effect of alcohol on portal hypertension in compensated cirrhosis secondary to hepatitis C.
    Garcia-Tsao, G
    Wongcharatrawee, S
    Escorsell, A
    Patch, D
    Grace, ND
    Burroughs, AK
    Makuch, R
    Katz, K
    Bosch, J
    Groszmann, RJ
    HEPATOLOGY, 2000, 32 (04) : 310A - 310A
  • [22] Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis
    Vizzutti, Francesco
    Arena, Umberto
    Romanelli, Roberto G.
    Rega, Luigi
    Foschi, Marco
    Colagrande, Stefano
    Petrarca, Antonio
    Moscarella, Stefania
    Belli, Giacomo
    Zignego, Anna Linda
    Marra, Fabio
    Laffi, Giacomo
    Pinzani, Massimo
    HEPATOLOGY, 2007, 45 (05) : 1290 - 1297
  • [23] REPRODUCIBILITY OF LIVER STIFFNESS IN CIRRHOSIS CAN AFFECT ITS ACCURACY FOR CLINICALLY SIGNIFICANT PORTAL HYPERTENSION DIAGNOSIS
    Yepes, I.
    Rincon, D.
    Ripoll, C.
    Fernandez, A.
    Matilla, A.
    Catalina, M. V.
    Salcedo, M.
    Miranda, J.
    Clemente, G.
    Banares, R.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S259 - S259
  • [24] Von Willebrand factor predicts clinically significant portal hypertension in patients with liver cirrhosis
    Homoncik, M.
    Ferlitsch, A.
    Reiberger, T.
    Ulbrich, G.
    Gangl, A.
    Peck-Radosavljevic, M.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S114 - S115
  • [25] Pharmacist led telemonitoring and titration of carvedilol for ambulatory patients with compensated cirrhosis and clinically significant portal hypertension
    Rodda, Sheridan
    McAinch, Chloe
    Morgan, Aparna
    Flanagan, Eliza
    Saxby, Edward
    Hunter, Jo
    Kirsa, Sue
    Bell, Sally
    Le, Suong
    JOURNAL OF HEPATOLOGY, 2023, 78 : S16 - S16
  • [26] Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation
    Berenguer, M
    Prieto, M
    Rayón, JM
    Mora, J
    Pastor, M
    Ortiz, V
    Carrasco, D
    San Juan, F
    Burgueño, MDJ
    Mir, J
    Berenguer, J
    HEPATOLOGY, 2000, 32 (04) : 852 - 858
  • [27] Spleen stiffness measurement improves non-invasive prediction of clinically significant portal hypertension in patients with compensated advanced chronic liver disease of mixed etiology
    Manfredi, Giulia Francesca
    Strada, Angelo
    Lotto, Mattia
    Romano, Valentina
    Bonafede, Vincenzo
    Burlone, Michela
    Minisini, Rosalba
    Pirisi, Mario
    Rigamonti, Cristina
    JOURNAL OF HEPATOLOGY, 2024, 80 : S627 - S627
  • [28] Noninvasive Prediction of Clinically Significant Portal Hypertension and Esophageal Varices in Patients With Compensated Liver Cirrhosis (vol 103, pg 1159, 2008)
    Berzigotti, Annalisa
    Gilabert, Rosa
    Abraldes, Juan G.
    Nicolau, Carlos
    Bru, Concepcio
    Bosch, Jaime
    Garcia-Pagan, Juan C.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 (07): : 1141 - 1141
  • [29] Novel serum biomarker of Golgi protein 73 for the diagnosis of clinically significant portal hypertension in patients with compensated cirrhosis
    Liu, Shanghao
    Ma, Jianzhong
    Chen, Ping
    Liu, Shirong
    Guo, Ying
    Tan, Mingjie
    Guo, Xiaoqing
    Feng, Yinong
    Wang, Qinghui
    Li, Wenhua
    Yang, Chengchen
    Gao, Bo
    Hua, Yongli
    Liu, Ning
    Song, Haolin
    He, Ruiling
    Wang, Ruiying
    Gao, Qi
    Liu, Chuan
    Qi, Xiaolong
    JOURNAL OF MEDICAL VIROLOGY, 2024, 96 (01)
  • [30] Varices on computed tomography are surrogate of clinically significant portal hypertension and can predict survival in compensated cirrhosis patients
    Lee, Dong Ho
    Ahn, Jhii-Hyun
    Chung, Jin Wook
    Kim, Young Ju
    Cha, Seung-Whan
    Kim, Moon Young
    Baik, Soon Koo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (02) : 450 - 457